Sugi Predict

Sugi Predict / Compounds / SCHEMBL3933394

SCHEMBL3933394

SCHEMBL3933394

CN(C)Cc1ccc(N/C(=C2\C(=O)Nc3ccccc32)c2ccc3[nH]cnc3c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 4/20 0.40
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ DYRK1A Q13627 2/20 0.35
▸ TLK2 Q86UE8 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ NAMPT P43490 1/20 0.34
▸ FOXO1 Q12778 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ IDO1 P14902 2/20 0.33
▸ LRRK2 Q5S007 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ WNT1 P04628 1/20 0.33
▸ POLB P06746 2/20 0.32
▸ HTT P42858 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ TDO2 P48775 1/20 0.32
▸ MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933400 0.93 RAB9A (0.45) SLC2A1NPC1RAB9AKMT2AMEN1
SCHEMBL3933391 0.83 MAPT (0.39) NPC1RAB9AKMT2AMEN1TLK2
SCHEMBL3943289 0.83 SLC2A1 (0.42) SLC2A1NPC1RAB9AKMT2ATDP1
SCHEMBL3943293 0.83 SLC2A1 (0.42) SLC2A1NPC1RAB9AKMT2ATDP1
SCHEMBL6323531 0.82 IDO1 (0.40) TDP1ROCK2IDO1LRRK2MAPT
SCHEMBL6323528 0.82 IDO1 (0.40) TDP1ROCK2IDO1LRRK2MAPT
SCHEMBL30979384 0.82 IDO1 (0.40) TDP1ROCK2IDO1LRRK2MAPT
SCHEMBL6326854 0.81 MAPT (0.41) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL6326859 0.81 MAPT (0.41) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL3933909 0.81 RAB9A (0.46) SLC2A1NPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 — — EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 — — US disclosed
EP-1551830-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-13 — — EP disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 — — US disclosed
WO-2004026829-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 SLC2A1 2424/4885NPC1 4723/4885RAB9A 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.